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Abstract
Background: Many studies have attempted to identify gene-gene interactions affecting asthma susceptibility.
However, these studies have typically used candidate gene approaches in limiting the genetic search space, and
there have been few searches for gene-gene interactions on a genome-wide scale. We aimed to conduct a
genome-wide gene-gene interaction study for asthma, using data from the GABRIEL Consortium.
Results: A two-stage study design was used, including a screening analysis (N = 1625 subjects) and a follow-up
analysis (N = 5264 subjects). In the screening analysis, all pairwise interactions among 301,547 SNPs were evaluated,
encompassing a total of 4.55 × 1010 interactions. Those with a screening interaction p-value < 10−5 were evaluated
in the follow-up analysis. No interaction selected from the screening analysis met strict statistical significance in the
follow-up (p-value < 1.45 × 10−7). However, the top-ranked interaction (rs910652 [20p13] × rs11684871 [2q14]) in the
follow-up (p-value = 1.58 × 10−6) was significant in one component of a replication analysis. This interaction was
notable in that rs910652 is located within 78 kilobases of ADAM33, which is one of the most well studied asthma
susceptibility genes. In addition, rs11684871 is located in or near GLI2, which may have biologically relevant roles in
asthma.
Conclusions: Using a genome-wide approach, we identified and found suggestive evidence of replication for a
gene-gene interaction in asthma involving loci that are potentially highly relevant in asthma pathogenesis.
Keywords: Asthma, Gene-gene interaction, Epistasis, ADAM33, GLI2
Background
Asthma is a chronic disease with a strong genetic
component in its etiology, having heritability esti-
mates ranging from 25 to 73 % [1, 2]. However, the
specific genetic factors that underlie this heritability
remain unclear, as most factors identified thus far
tend to have weak effect sizes and are poorly repli-
cated across studies [3, 4]. Gene-gene interaction, the
phenomenon where the phenotypic effect of a variant
at one genetic locus depends on variants at other loci
[5, 6], is one possible explanation for this “missing
heritability” and the lack of replication of genetic ef-
fects for many complex diseases [7–9]. Thus, the
identification of gene-gene interactions could enable a
greatly improved understanding of the genetic eti-
ology of asthma.
More than 45 studies have attempted to identify
gene-gene interactions in asthma, with over 190 sig-
nificant interactions reported thus far [10]. However,
these studies have tended to use candidate gene ap-
proaches to narrow the genetic space in which to
search for interactions, typically focusing on loci that
have been reported to show significant marginal ef-
fects (i.e., effects that manifest when loci are assessed
individually). To our knowledge, only one asthma as-
sociation study involving a genome-wide search for
gene-gene interactions has been published, with null
findings [11]. Although this may be due in part to
the lower likelihood of publication of null findings, it
appears that the search space of pairwise interactions
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In order to identify interactions involving loci that
might not otherwise be considered, we aimed to con-
duct a genome-wide search for gene-gene interactions
in asthma susceptibility. Data from the GABRIEL
Consortium genome-wide association study of asthma
[12] were obtained for this purpose, which included a
total of 4186 cases and 3916 controls. To maintain
power in detecting an interaction, we used a two-
stage screening and follow-up approach. In this de-
sign, the screening stage was used to conduct the ex-
haustive genome-wide search for interactions, and the
follow-up stage was used to assess all interactions
with a p-value < 10−5. In addition, a preliminary at-
tempt at replication was made for the most signifi-
cant interaction identified from the follow-up.
Methods
Study datasets
All data in the current study were obtained from the
GABRIEL Consortium [12] (European Genome-
phenome Archive Study ID: EGAS00000000077). Ap-
proval for the use of this data was obtained from the
Gabriel Consortium Data Access Committee. Data from
12 of the GABRIEL study centers were included
(Table 1). In this paper, we refer to any dataset particular
to an individual study center as a “sub-study” dataset.
Case/control status, sex, and genotype information were
available, while age and all other information were not
available. In general, cases were subjects with self-
reported doctor-diagnosed asthma, although some sub-
studies had alternative definitions (Table 1). In particular,
Table 1 Sub-studies included from the GABRIEL Consortium
Study
component
Sub-study Reference Country of
origin




Screening GABRIEL-AS [28] Austria,
Germany,
Switzerland
Ever had doctor-diagnosed asthma or
had asthmatic bronchitis at least twice
(self-report).
Did not ever have doctor-diagnosed
asthma and no asthmatic bronchitis di-
agnosed at least twice (self-report).
802 823
Follow-up BAMSE [30] Sweden Ever had doctor-diagnosed asthma
(self-report).
Did not have a history of asthma or
other allergic diseases (self-report).
226 235
BUSSELTON [31] Australia Ever had doctor-diagnosed asthma
(self-report).
Did not ever have doctor-diagnosed
asthma (self-report).
520 685
EGEA [32] France Ever had asthma attacks (self-report). Did not ever have asthma attacks (self-
report).
120 444
KMSU [33] Russia Asthma diagnosed on the basis of
symptoms (recurrent cough, wheezing,
or dyspnea), airway obstruction
reversibility, or airway methacholine
hyper-responsiveness.
No symptoms or history of allergic





Ever had doctor-diagnosed asthma
(self-report).
Did not have a history of asthma or
other allergic diseases (self-report).
174 187
SAPALDIA [35] Switzerland Ever had asthma (self-report). Did not ever have asthma (self-report). 581 880
UFA N/A Russia Asthma diagnosed on the basis of
clinical examination, family and
medication history, and lung function
tests.
No symptoms or history of asthma or
other pulmonary disease, no
symptoms or history of atopy, no first-
degree relatives with a history of
asthma or atopy.
333 333
Sub-total (Follow-up) 2239 3025
Replication AUGOSA [36] United
Kingdom
Severe asthma (determined based on





Ever had doctor-diagnosed asthma
(self-report).
Did not ever have doctor-diagnosed
asthma (self-report).
57 68
MAS [38] Germany Ever had doctor-diagnosed asthma. N/A 173 0
SEVERE [39] United
Kingdom
Severe asthma (determined based on
clinical assessments and control of
symptoms)
N/A 290 0
Sub-total (Replication) 1145 68
Total (all) 4186 3916
More complete case/control definitions may be available in the indicated references or the supplement to Moffatt et al. [12]. Subject counts reflect final numbers
for inclusion, after quality control procedures were applied
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the AUGOSA and SEVERE sub-studies involved subjects
with severe asthma. The MAS, AUGOSA, and SEVERE
sub-studies only had cases available. All subjects were
genotyped on the Illumina Human610 quad array (N =
582,892 single nucleotide polymorphisms [SNPs]).
Quality control (QC)
Subjects were excluded if any of the following were true:
having a subject call rate < 95 %; having an ambiguous
SNP-estimated sex (X-chromosome homozygosity, F, be-
tween 0.2 and 0.8); being flagged for removal due to re-
latedness with other subjects; and being flagged as a
principal components outlier. Subject relatedness was
determined by calculating pi-hat (proportion identical by
descent) between every pair of subjects; one randomly
chosen subject of every pair with pi-hat ≥ 0.20 was
flagged for removal. Principal components analysis was
performed using EIGENSTRAT; a subject was flagged as
an outlier if he or she had a value >6 standard deviations
on the top 10 components. Both subject relatedness and
principal components analysis were assessed in linkage-
disequilibrium (LD) pruned datasets (based on pairwise
SNP correlations; r2 threshold of 0.5).
SNPs were excluded if any of the following were true:
unable to convert from hg18 to hg19 reference genome
coordinates; having a SNP call rate <98 % in either cases
or controls (for MAS, AUGOSA, and SEVERE, only
cases were considered); and having a test for deviation
from Hardy-Weinberg equilibrium (HWE) with p-value
< 10–4 among controls (for MAS, AUGOSA, and SE-
VERE, the criteria was p-value < 10−7 among cases).
All QC procedures were performed within each sub-
study individually. QC exclusion counts and final subject
characteristics are shown in Additional file 1: Tables S1,
S2 and S3.
Population stratification
To check for test statistic inflation due to population
stratification or other sources, quantile-quantile (QQ)
plots of observed vs. expected-under-the-null p-values
were evaluated. This was performed for both marginal
effect p-values and interaction p-values, within each
sub-study (for case-only studies, only interaction QQ
plots were evaluated). P-values from the follow-up inter-
action meta-analysis were also examined via QQ plots.
Little or no inflation was noted (Additional file 1: Figure
S1). At most, a minor amount of inflation was noted for
UFA in the marginal effects, but this did not appear to
manifest in the interaction effects.
Analytical methods
Screening analysis
The largest sub-study available, GABRIEL-AS (GABRIEL
Advanced Surveys), was used as a screening dataset. All
pairwise interactions between SNPS with minor allele
frequency (MAF) ≥ 0.20, only including chromosomes 1
through 22, were analyzed for the outcome of asthma.
This included N = 301,547 SNPs and N = 4.55 × 1010 in-
teractions. The search space was not trimmed for LD,
and thus a portion of these interactions was likely statis-
tically redundant. The analysis was performed using the
logistic regression (−lr) function in the CASSI Genome-
Wide Interaction Analysis Software package, due to its
computational speed advantages when performing epis-
tasis (gene-gene interaction) analyses (version 2.50;
https://www.staff.ncl.ac.uk/richard.howey/cassi/
index.html). All interactions with a p-value < 10−5 in this
analysis were tested again using the –epistasis function
in PLINK (version 1.07; http://pngu.mgh.harvard.edu/
~purcell/plink/) [13]. This was done in order to confirm
that interactions met the same p-value threshold using
both methods, since minor differences in p-values be-
tween the methods were noted. All interactions with a
p-value < 10−5 from both methods (N = 345,034 interac-
tions) were included for the follow-up analysis. At this
significance level, the GABRIEL-AS study has greater
than 90 % power to detect interactions with an inter-
action odds ratio (OR) 2.5 or more, for SNPs with MAF
0.20 or more (for additional power estimates, see Add-
itional file 1: Table S4).
Follow-up analysis
The seven next-largest studies containing both cases and
controls, including BAMSE, BUSSELTON, EGEA, KMSU,
PIAMA, SAPALDIA, and UFA, were used as the follow-up
datasets. All interactions that passed the screening analysis
were analyzed in each of these datasets, individually, using
the –epistasis function in PLINK. Each such analysis in-
volved a logistic regression model that included a main ef-
fect variable for each SNP and an interaction variable
(defined as the product of the main effects variables), with
each SNP variable coded additively (taking on the values 0,
1, or 2, depending on the number of copies of the non-
referent allele present). Asthma (log odds of being a case)
was the outcome. All studies used the same non-referent
allele for each SNP; this was the minor allele among con-
trols in GABRIEL-AS. Interaction p-values originated from
a test of the null hypothesis that the interaction variable
parameter is equal to zero, after adjusting for the main ef-
fects. Gene-gene interaction is represented in these models
as deviation from additivity of combined SNP effects on the
log-odds scale of disease. SAS version 9.3 (SAS Insti-
tute; Cary, NC) was used to obtain full parameter es-
timates (i.e., including both main effects and
interaction terms) of the most significant interactions.
Parameter estimates were meta-analyzed via fixed ef-
fects or random effects models, across the N = 7
follow-up studies. Heterogeneity was assessed via
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calculations of I2 and the Q test. If an interaction had
an I2 < 50 % and a Q test p-value ≥ 0.10, then fixed ef-
fects estimates were used; otherwise, random effects
estimates were used. Meta-analyses were performed
using R version 3.11 (http://www.r-project.org) and
the package “meta”, version 3.7-1 (http://cran.r-projec-
t.org/web/packages/meta/). The top ten most signifi-
cant interactions from the follow-up, as ranked by
meta-analysis interaction p-value, are listed in Add-
itional file 1: Table S5. For the follow-up meta-
analysis, statistical significance was defined as 0.05
corrected for 345,034 tests of interaction (p < 1.45 ×
10−7). At this significance level, an approximate esti-
mation of power indicates that the follow-up analysis
has greater than 90 % power to detect interactions
with an interaction odds ratio 1.75 or more, for SNPs
with MAF 0.20 or more (for additional power esti-
mates, see Additional file 1: Table S4).
Replication analysis
The smallest case-control study (KARELIA) and the
case-only studies (MAS, AUGOSA, and SEVERE) were
used as replication datasets. In KARELIA, the interac-
tions chosen for replication were analyzed using logistic
regression modeling, as described above. In MAS,
AUGOSA, and SEVERE, the interactions were analyzed
using the adjusted fast epistasis case-only test (−afe-co-
only) in CASSI, which is a test of correlation between al-
leles at two different SNPs. Under the assumption that
such a correlation does not exist in controls, the case-
only test reflects a test for gene-gene interaction, since
allelic co-occurrence might indicate that the alleles
jointly affect disease risk [14]. More specifically, an inter-
action term from a logistic regression model involving
binary predictors can be seen to be equivalent to the ra-
tio of the OR of association between alleles in cases to
the OR of association between alleles in controls. There-
fore, if the OR of association between alleles in controls
is one, then the OR of association between alleles in
cases is equal to the interaction odds ratio [14]. How-
ever, findings from case-only tests must be interpreted
with abundant caution, since the “no correlation among
controls” assumption is potentially suspect given the ef-
fects of linkage disequilibrium [6]. Results from the four
replication datasets were not meta-analyzed, due to het-
erogeneity in the tests used and the phenotypes assessed
(AUGOSA and SEVERE involved severe asthma cases,
whereas KARELIA and MAS cases were not defined
based on severity), as well as due to the unidentified
sources of heterogeneity that led to discordance in
the directions of effects (Table 2). For the replication
analysis, significance was defined as p < 0.05. Given
the use of the case-only approach for three of the
four replication datasets, results from these analyses
were considered preliminary, as any significant find-
ings will require further study using a more robust
case-control approach.
Assessment of interactions surrounding the top hit in the
follow-up analysis
Variants located within intervals spanning 100 kilobases
(Kb) upstream and downstream of rs11684871 (chromo-
some 2) and rs910652 (chromosome 20) were imputed
using IMPUTE2 (https://mathgen.stats.ox.ac.uk/impute/
impute_v2.html) and 1000 Genomes reference haplotype
panels (Phase 1 integrated variant set release v3) [15].
This was done within each sub-study individually, after
quality control procedures had been applied. The buffer
size was set as 250 Kb, and reference SNPs with MAF <
0.01 among 1000 Genomes subjects of European descent
were filtered (ignored) during the imputation. In the
screening and follow-up datasets, all QC-passed directly
genotyped SNPs within the interval specified above, and
all imputed SNPs with certainty ≥ 0.80 and info ≥ 0.50,
were included for analysis. SNPs were excluded from
analysis if they had a MAF < 0.10 (based on frequencies
in GABRIEL-AS controls). Pairwise interactions between
chromosome 2 and 20 SNPs were assessed using the
PLINK –epistasis function (N = 124,502 interactions).
Statistical significance for the follow-up studies in ana-
lyzing interactions involving these regions was set as
1.06 × 10−7 (0.05 corrected for 345,034 + 124,502 =
469,536 interactions). For replication in the case-only
sub-studies, the CASSI case-only analysis was used, as
described above. Since the imputation quality was high
(median concordance across the 12 sub-studies: 95.6 for
chromosome 2 SNPs, 96.5 for chromosome 20 SNPs),
SNPs were analyzed using rounded genotypes, where the
highest probability genotype was called as 1 if its prob-
ability was ≥ 0.90, and the other two genotypes were
called as 0; if no probability was ≥ 0.90, then all three ge-
notypes were set as missing.
Regulatory annotation
In order to identify any possible functional, regulatory sites
within the genomic intervals surrounding the SNPs in-
volved in the top interaction (as specified above), we used
data from RegulomeDB [16] and GTEx [17]. Specifically,
RegulomeDB Version 1.1 was used to identify all genomic
positions having a RegulomeDB score of 1 or 2 (i.e., sites
that are likely to affect transcription factor binding). GTEx
Analysis Version 4 was used to identify all significant
eQTL SNPs for the gene targets of ADAM33,
HSPA12B, SIGLEC1, and GLI2 (as determined from
any tissue type). Only three eQTL SNPs, all for
ADAM33, were found (rs609203, rs2853211, and
rs554743). These annotations were used to illustrate
Fig. 1.
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Results
Screening analysis
In the screening analysis, all 4.55 × 1010 pairwise in-
teractions among the 301,547 SNPs with MAF ≥ 0.20
were assessed. The most significant interaction from
this analysis (rs12289833 [11q25] × rs5027694 [13q13])
had a p-value of 3.43 × 10−10. A total of 345,034 inter-
actions with a p-value < 10−5 from the screening ana-
lysis were included for further evaluation in the
follow-up analysis.
Follow-up analysis
In the follow-up analysis, no interaction exceeded the pre-
specified significance threshold of p < 1.45 × 10−7 after
being meta-analyzed across the seven follow-up sub-
studies. The top-ranked interaction in the follow-up
(rs910652 [20p13] × rs11684871 [2q14]) had a meta-
analysis p-value of 1.58 × 10−6, although the inter-
action odds ratio was not consistent with that of the
screening analysis (Fig. 2; Table 2). Interestingly,
rs910652 is located approximately 78 kilobases upstream
of ADAM33, which is one of the most well-studied sus-
ceptibility loci for asthma. The other SNP, rs11684871, is
either upstream, or in an intron, of GLI2, depending on
which splice variant is considered. Due to the possible in-
volvement of the ADAM33 locus in this interaction, a
more detailed investigation of the surrounding pairwise
chromosomal space was performed. Specifically, we
Table 2 Model estimates of interaction between 20p13 and 2q14
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Case-only OR (95 % CI) Case-only p-value Case-only OR (95 % CI) Case-only p-value
MAS 1.37 (1.01, 1.86) 4.20 × 10−2 0.96 (0.69, 1.34) 8.08 × 10−1
AUGOSA 1.18 (0.98, 1.42) 7.34 × 10−2 0.99 (0.83, 1.19) 9.42 × 10−1
SEVERE 0.79 (0.59, 1.07) 1.31 × 10−1 0.75 (0.55, 1.01) 6.10 × 10−2
See the Methods section for model descriptions. Major/minor alleles, respectively, are indicated next to SNP RSIDs. OR: odds ratio. CI: confidence interval. P-value:
p-value for the test of the null hypothesis that the respective parameter estimate is equal to zero. Meta-analysis: fixed effects meta-analysis for the follow-up stud-
ies. I2: percentage of effect variability due to heterogeneity between studies. Q: p-value from a Q test for heterogeneity. The case-only ORs reflect correlation be-
tween alleles of the two SNPs, and the p-value is for the test of the null hypothesis that no such correlation exists. Characteristics of the SNPs are shown in
Additional file 1: Tables S6 and S7
Murk and DeWan BMC Genetics  (2016) 17:102 Page 5 of 9
imputed variants 100 kilobases upstream and downstream
of each SNP, and assessed all interactions between these
areas (N = 124,502 interactions; Fig. 1). In these areas, the
strongest interaction (rs1018491 × rs67959717) had a
p-value of 5.78 × 10−8, which exceeded a conservative
significance threshold of 1.06 × 10−7 (Table 2; Fig. 1).
Replication analysis
Next, we evaluated the rs910652 × rs11684871 and
rs1018491 × rs67959717 interactions in the replication
analysis (Fig. 2; Table 2). A case-only interaction analysis
was performed for MAS, AUGOSA, and SEVERE, since
these datasets did not contain controls. Two of these
sub-studies, AUGOSA and SEVERE, involved subjects
with severe asthma. The rs910652 × rs11684871 inter-
action was significant at p < 0.05 in MAS (p = 0.042) and
approached significance in AUGOSA (p = 0.073). The
case-only odds ratios for these studies were consistent in
direction with the follow-up studies (confirmed by also
performing case-only analyses in the follow-up studies;
Fig. 1 Gene-gene interactions between 20p13 and 2q14. P-values for interactions between variants within 0.1 megabases (Mb) of rs910652 and rs11684871
are represented. Gene annotations are from LocusZoom (http://locuszoom.sph.umich.edu/locuszoom/); regulatory annotations are from RegulomeDB and
GTEx (see the Methods section). The side plots show LD structure; stronger colors on these plots indicate higher pairwise LD as measured by D’ (generated
via Haploview [http://www.broadinstitute.org/haploview]). Interaction p-values and LD measures from the screening dataset (a) and follow-up datasets (meta-
analysis p-values) (b) are shown. The green lines identify correspondence between genomic positions and LD plot positions, for the highlighted variants
Fig. 2 Forest plot of effect estimates for the interaction between rs910652 and rs11684871. Parts of this figure were made with RevMan 5.3
(http://tech.cochrane.org/revman)
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not shown). The interaction was not significant and in
opposite direction in KARELIA and SEVERE. The
rs1018491 × rs67959717 interaction was not significant
in any replication dataset; it approached significance
(p = 0.061) in SEVERE, although the direction was op-
posite that of the direction in the follow-up studies.
Discussion
The top-ranked gene-gene interaction in the follow-up ana-
lysis (rs910652 × rs11684871) involved a SNP (rs910652) lo-
cated near the ADAM33 gene. ADAM33 was the first gene
to be linked to asthma susceptibility, and numerous studies
have confirmed associations between this gene and asthma,
although the specific causal variants are unclear and there
are notable inconsistencies across studies [18]. Despite the
fact that rs910652 is located in a flanking gene (HSPA12B),
and does not appear to be in strong LD with ADAM33
(Fig. 1), one possible explanation for our findings is that this
SNP could be tagging a variant that influences the regula-
tion of nearby genes. This is indirectly suggested by our
observation that the strongest interaction in the surround-
ing region (rs1018491 × rs67959717) involves a SNP
(rs1018491) that is located intergenically, closer to
ADAM33 and between SIGLEC1 and HSPA12B. This SNP
is 38 bases away from a genomic position (chr20:3701170;
itself not imputed in the current study) that may affect
transcription factor binding (RegulomeDB score: 2b; puta-
tive bound protein: TCF12). However, the rs1018491 ×
rs67959717 interaction was not replicated, which could
suggest that the functional variant is actually located else-
where on chromosome 20. The closest known ADAM33
eQTL (rs609203) is in an intron of the SIGLEC1 gene
(Fig. 1), but the strongest interaction involving this SNP
was of modest significance (rs609203 × rs4848623; follow-
up interaction p-value: 0.0026; data not shown). An alter-
native explanation is that HSPA12B itself is the functional
gene of the interaction on chromosome 20. This gene
does not have a clear role in asthma, but one study has re-
ported its association with lung function at the same SNP
we identified (rs910652) [19].
The other gene in the identified interaction, GLI2, has
been reported to be involved in T-cell function [20, 21]
and TGFβ expression [22], which are both well-known
components of asthma pathogenesis [23, 24]. In addition,
this gene is known to play a role in lung development [25,
26]. Thus, it is highly plausible that GLI2 has biological
relevance in asthma. Transcriptional activation of GLI2
depends on SMAD3 [27], which was one of the top
asthma-associated genes in the original GABRIEL study
[12]. The functional interaction that underlies our ob-
served statistical interaction is unclear, as such an inter-
action between GLI2 and either ADAM33, SIGLEC1, or
HSPA12B has not been described. However, suggestions
of a biological relationship between GLI2 and ADAM33
can perhaps be seen in the fact that both of these genes
are regulated by TGFβ [18, 27].
A limitation to our results is that the directions of ef-
fect of the identified interactions were inconsistent be-
tween the screening and follow-up analyses (Table 2).
The simplest explanation for this is that the detected sig-
nal arose by chance in the screening analysis. An alter-
native, mechanistic explanation is that the direction of
the observed gene-gene interaction depends on an un-
known environmental exposure (e.g., when a subject is ex-
posed, the gene-gene interaction is epistatically protective,
and when unexposed, it is epistatically deleterious) that
has differences in prevalence between the screening and
follow-up studies. Although most of the included GAB-
RIEL sub-studies are relatively similar to one another, one
notable difference between the GABRIEL-AS (screening)
sub-study and the others is that, in GABRIEL-AS, subjects
were recruited from rural areas [28], which may have an
overall protective effect on asthma [29]. It is possible that
different variants on chromosome 20 are involved in this
hypothetical environmental dependency, given that the
gene-gene interaction signal maximizes at different
chromosomal locations between the screening and follow-
up studies (Fig. 1).
An additional limitation is that we relied on case-only
analysis for replication. This method assumes that cor-
relation between alleles only exists in cases (due to
gene-gene interaction affecting the phenotype) and not
in controls; this assumption could be violated, particu-
larly if linkage disequilibrium exists between the SNPs.
Since the interacting SNPs are on different chromo-
somes, we believe that this assumption is not unreason-
able, but nevertheless a case-control approach is
required to confirm the replication. Finally, the screen-
ing analysis was powered to detect interaction ORs of
2.50 and above (for MAF 0.2 and above at each SNP);
this may be an unrealistically high effect estimate, and
the study likely missed interactions of weaker effect and/
or less common SNPs from the screening stage.
Conclusions
In summary, using a genome-wide approach of screening
for gene-gene interactions, we identified and found suggest-
ive evidence of replication for an interaction in asthma
(rs910652 × rs11684871), where one of the participating
SNPs (rs910652) is in close proximity to ADAM33 and the
other (rs11684871) is located in or near GLI2. Both SNPs
are highly plausible asthma risk variants, given known asso-
ciations between ADAM33 and asthma, a previously re-
ported association between rs910652 and lung function,
and the roles of GLI2 in T-cell regulation and lung develop-
ment. To our knowledge, GLI2 has not been previously im-
plicated in asthma susceptibility. This could be explained
by our observations that the GLI2 SNPs did not manifest
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any marginal effects (Additional file 1: Tables S6-S7), sug-
gesting that these SNPs would be undetected in the trad-
itional association study design that examines each locus
individually.
Further investigation is required to confirm the puta-
tive interaction identified in the present study, as well as
to identify the possible causal loci underlying the inter-
action. If the interaction is genuine, it could provide new
insight into the biological role of ADAM33 or its neigh-
boring genes in asthma susceptibility, and may also
emphasize GLI2 as a new gene of investigation for
asthma. This study may also inform general strategies
for epistasis investigations: given that one putatively
interacting locus is in a region previously associated with
asthma or lung function (ADAM33/HSPA12B), and the
other is highly biologically plausible (GLI2), this study
provides evidence in support of investigational strategies
that restrict the epistasis search space to features with
prior disease relevance.
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